Search

Your search keyword '"Ramirez Morales, Rafael"' showing total 17 results
Start Over Author "Ramirez Morales, Rafael"
17 results on '"Ramirez Morales, Rafael"'

1. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study

Author

Vitale, Alessandro, Ramirez Morales, Rafael, Zanus, Giacomo, Farinati, Fabio, Burra, Patrizia, Angeli, Paolo, Frigo, Anna Chiara, Del Poggio, Paolo, Rapaccini, Gianludovico, Di Nolfo, Maria Anna, Benvegnù, Luisa, Zoli, Marco, Borzio, Franco, Giannini, Edoardo Giovanni, Caturelli, Eugenio, Chiaramonte, Maria, Trevisani, Franco, and Cillo, Umberto

Published
2011
Full Text
View/download PDF

2. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database

Author

Vitale, Alessandro, primary, Svegliati-Baroni, Gianluca, additional, Ortolani, Alessio, additional, Cucco, Monica, additional, Dalla Riva, Giulio V, additional, Giannini, Edoardo G, additional, Piscaglia, Fabio, additional, Rapaccini, Gianludovico, additional, Di Marco, Mariella, additional, Caturelli, Eugenio, additional, Zoli, Marco, additional, Sacco, Rodolfo, additional, Cabibbo, Giuseppe, additional, Marra, Fabio, additional, Mega, Andrea, additional, Morisco, Filomena, additional, Gasbarrini, Antonio, additional, Foschi, Francesco Giuseppe, additional, Missale, Gabriele, additional, Masotto, Alberto, additional, Nardone, Gerardo, additional, Raimondo, Giovanni, additional, Azzaroli, Francesco, additional, Vidili, Gianpaolo, additional, Oliveri, Filippo, additional, Pelizzaro, Filippo, additional, Ramirez Morales, Rafael, additional, Cillo, Umberto, additional, Trevisani, Franco, additional, Miele, Luca, additional, Marchesini, Giulio, additional, and Farinati, Fabio, additional

Published
2021
Full Text
View/download PDF

3. Tumefactive multiple sclerosis

Author

Ortega-Sierra, Michael Gregorio, primary, Delgado-Marrugo, Raul David, additional, Campo-Bedoya, Cristian Camilo, additional, Marín-Pérez, Geraldine, additional, Gómez-Caballero, Rhonald, additional, Hernández-Nieto, Bryan D., additional, Gutiérrez-Castillo, Gabriel Fernando, additional, Bello-Cordero, John Fredys, additional, Torres-Báez, Mónica Alejandra, additional, Ramirez-Morales, Rafael Ricardo, additional, Lozada-Martinez, Ivan David, additional, and Moscote-Salazar, Luis Rafael, additional

Published
2021
Full Text
View/download PDF

4. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database

Author

Vitale, Alessandro, Svegliati-Baroni, Gianluca, Ortolani, Alessio, Cucco, Monica, Dalla Riva, Giulio V, Giannini, Edoardo G, Piscaglia, Fabio, Rapaccini, Gianludovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Oliveri, Filippo, Pelizzaro, Filippo, Ramirez Morales, Rafael, Cillo, Umberto, Trevisani, Franco, Miele, Luca, Marchesini, Giulio, Farinati, Fabio, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Miele, Luca (ORCID:0000-0003-3464-0068), Vitale, Alessandro, Svegliati-Baroni, Gianluca, Ortolani, Alessio, Cucco, Monica, Dalla Riva, Giulio V, Giannini, Edoardo G, Piscaglia, Fabio, Rapaccini, Gianludovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Oliveri, Filippo, Pelizzaro, Filippo, Ramirez Morales, Rafael, Cillo, Umberto, Trevisani, Franco, Miele, Luca, Marchesini, Giulio, Farinati, Fabio, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), and Miele, Luca (ORCID:0000-0003-3464-0068)

Abstract

Background Metabolic dysfunction-associated fatty liver disease (MAFLD) represents a new inclusive definition of the whole spectrum of liver diseases associated to metabolic disorders. The main objective of this study was to compare patients with MAFLD and non-MAFLD with hepatocellular carcinoma (HCC) included in a nationally representative cohort. Methods We analysed 6882 consecutive patients with HCC enrolled from 2002 to 2019 by 23 Italian Liver Cancer centres to compare epidemiological and future trends in three subgroups: pure, single aetiology MAFLD (S-MAFLD); mixed aetiology MAFLD (metabolic and others, M-MAFLD); and non-MAFLD HCC. Results MAFLD was diagnosed in the majority of patients with HCC (68.4%). The proportion of both total MAFLD and S-MAFLD HCC significantly increased over time (from 50.4% and 3.6% in 2002-2003, to 77.3% and 28.9% in 2018-2019, respectively, p<0.001). In Italy S-MAFLD HCC is expected to overcome M-MAFLD HCC in about 6 years. Patients with S-MAFLD HCC were older, more frequently men and less frequently cirrhotic with clinically relevant portal hypertension and a surveillance-related diagnosis. They had more frequently large tumours and extrahepatic metastases. After weighting, and compared with patients with non-MAFLD, S-MAFLD and M-MAFLD HCC showed a significantly lower overall (p=0.026, p=0.004) and HCC-related (p<0.001, for both) risk of death. Patients with S-MAFLD HCC showed a significantly higher risk of non-HCC-related death (p=0.006). Conclusions The prevalence of MAFLD HCC in Italy is rapidly increasing to cover the majority of patients with HCC. Despite a less favourable cancer stage at diagnosis, patients with MAFLD HCC have a lower risk of HCC-related death, suggesting reduced cancer aggressiveness.

Published
2021

5. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database

Author

Vitale, Alessandro, Svegliati-Baroni, Gianluca, Ortolani, Alessio, Cucco, Monica, Dalla Riva, Giulio V, Giannini, Edoardo G, Piscaglia, Fabio, Rapaccini, Gianludovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Oliveri, Filippo, Pelizzaro, Filippo, Ramirez Morales, Rafael, Cillo, Umberto, Trevisani, Franco, Miele, Luca, Marchesini, Giulio, and Farinati, Fabio

Abstract

BackgroundMetabolic dysfunction-associated fatty liver disease (MAFLD) represents a new inclusive definition of the whole spectrum of liver diseases associated to metabolic disorders. The main objective of this study was to compare patients with MAFLD and non-MAFLD with hepatocellular carcinoma (HCC) included in a nationally representative cohort.MethodsWe analysed 6882 consecutive patients with HCC enrolled from 2002 to 2019 by 23 Italian Liver Cancer centres to compare epidemiological and future trends in three subgroups: pure, single aetiology MAFLD (S-MAFLD); mixed aetiology MAFLD (metabolic and others, M-MAFLD); and non-MAFLD HCC.ResultsMAFLD was diagnosed in the majority of patients with HCC (68.4%). The proportion of both total MAFLD and S-MAFLD HCC significantly increased over time (from 50.4% and 3.6% in 2002–2003, to 77.3% and 28.9% in 2018–2019, respectively, p<0.001). In Italy S-MAFLD HCC is expected to overcome M-MAFLD HCC in about 6 years. Patients with S-MAFLD HCC were older, more frequently men and less frequently cirrhotic with clinically relevant portal hypertension and a surveillance-related diagnosis. They had more frequently large tumours and extrahepatic metastases. After weighting, and compared with patients with non-MAFLD, S-MAFLD and M-MAFLD HCC showed a significantly lower overall (p=0.026, p=0.004) and HCC-related (p<0.001, for both) risk of death. Patients with S-MAFLD HCC showed a significantly higher risk of non-HCC-related death (p=0.006).ConclusionsThe prevalence of MAFLD HCC in Italy is rapidly increasing to cover the majority of patients with HCC. Despite a less favourable cancer stage at diagnosis, patients with MAFLD HCC have a lower risk of HCC-related death, suggesting reduced cancer aggressiveness.

Published
2023
Full Text
View/download PDF

6. Use of N-acetylcysteine during liver procurement: A prospective randomized controlled study

Author

DʼAmico, Francesco, Vitale, Alessandro, Piovan, Donatella, Bertacco, Alessandra, Ramirez Morales, Rafael, Chiara Frigo, Anna, Bassi, Domenico, Bonsignore, Pasquale, Gringeri, Enrico, Valmasoni, Michele, Garbo, Greta, Lodo, Enrico, DʼAmico, Francesco Enrico, Scopelliti, Michele, Carraro, Amedeo, Gambato, Martina, Brolese, Alberto, Zanus, Giacomo, Neri, Daniele, and Cillo, Umberto

Published
2013
Full Text
View/download PDF

7. Tumefactive multiple sclerosis. A rare but serious variable in multiple sclerosis.

Author

Ortega-Sierra, Michael Gregorio, Delgado-Marrugo, Raul David, Campo-Bedoya, Cristian Camilo, Marín-Pérez, Geraldine, Gómez-Caballero, Rhonald, Nieto, Bryan D. Hernández, Gutiérrez-Castillo, Gabriel Fernando, Bello-Cordero, John Fredys, Báez, Mónica Alejandra Torres, Ramirez-Morales, Rafael Ricardo, Lozada-Martinez, Ivan David, and Moscote-Salazar, Luis Rafael

Subjects
MULTIPLE sclerosis, BRAIN damage
Abstract

Tumefactive multiple sclerosis is a rare variant of multiple sclerosis, characterized by the presence of brain lesions that may be solitary or multiple. Considering that these lesions have a pseudotumoral appearance, it is a challenge to differentiate them from central nervous system neoplasms through neuroimaging. Many cases are associated with the administration of monoclonal antibodies, and due to an increase in the incidence of cancer globally, it is expected that secondary to chemotherapeutic treatments, more and more cases may appear. Taking into account the above, the objective of this review is to review aspects of usefulness in clinical practice, on the diagnosis and approach of this pathological condition [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

8. Erratum: A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list (Journal of Hepatology (2013) 60 (290-297))

Author

Vitale, A, Volk, M, De Feo, T, Burra, P, Frigo, A, Ramirez Morales, R, De Carlis, L, Belli, L, Colledan, M, Fagiuoli, S, Rossi, G, Andorno, E, Baccarani, U, Regalia, E, Vivarelli, M, Donataccio, M, Cillo, U, Vitale, Alessandro, Volk, Michael L., De Feo, Tullia Maria, Burra, Patrizia, Frigo, Anna Chiara, Ramirez Morales, Rafael, De Carlis, Luciano, Belli, Luca, Colledan, Michele, Fagiuoli, Stefano, Rossi, Giorgio, Andorno, Enzo, Baccarani, Umberto, Regalia, Enrico, Vivarelli, Marco, Donataccio, Matteo, Cillo, Umberto, Vitale, A, Volk, M, De Feo, T, Burra, P, Frigo, A, Ramirez Morales, R, De Carlis, L, Belli, L, Colledan, M, Fagiuoli, S, Rossi, G, Andorno, E, Baccarani, U, Regalia, E, Vivarelli, M, Donataccio, M, Cillo, U, Vitale, Alessandro, Volk, Michael L., De Feo, Tullia Maria, Burra, Patrizia, Frigo, Anna Chiara, Ramirez Morales, Rafael, De Carlis, Luciano, Belli, Luca, Colledan, Michele, Fagiuoli, Stefano, Rossi, Giorgio, Andorno, Enzo, Baccarani, Umberto, Regalia, Enrico, Vivarelli, Marco, Donataccio, Matteo, and Cillo, Umberto

Published
2014

9. Erratum: A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list (Journal of Hepatology (2013) 60 (290-297))

Author

Vitale, Alessandro, Vitale, A, Volk, M, De Feo, T, Burra, P, Frigo, A, Ramirez Morales, R, De Carlis, L, Belli, L, Colledan, M, Fagiuoli, S, Rossi, G, Andorno, E, Baccarani, U, Regalia, E, Vivarelli, M, Donataccio, M, Cillo, U, Vitale, Alessandro, Volk, Michael L., De Feo, Tullia Maria, Burra, Patrizia, Frigo, Anna Chiara, Ramirez Morales, Rafael, De Carlis, Luciano, Belli, Luca, Colledan, Michele, Fagiuoli, Stefano, Rossi, Giorgio, Andorno, Enzo, Baccarani, Umberto, Regalia, Enrico, Vivarelli, Marco, Donataccio, Matteo, Cillo, Umberto, Vitale, Alessandro, Vitale, A, Volk, M, De Feo, T, Burra, P, Frigo, A, Ramirez Morales, R, De Carlis, L, Belli, L, Colledan, M, Fagiuoli, S, Rossi, G, Andorno, E, Baccarani, U, Regalia, E, Vivarelli, M, Donataccio, M, Cillo, U, Vitale, Alessandro, Volk, Michael L., De Feo, Tullia Maria, Burra, Patrizia, Frigo, Anna Chiara, Ramirez Morales, Rafael, De Carlis, Luciano, Belli, Luca, Colledan, Michele, Fagiuoli, Stefano, Rossi, Giorgio, Andorno, Enzo, Baccarani, Umberto, Regalia, Enrico, Vivarelli, Marco, Donataccio, Matteo, and Cillo, Umberto

Published
2014

10. Erratum to “A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list” [J Hepatol 2013;60:290–297]

Author

Vitale, Alessandro, primary, Volk, Michael L., additional, De Feo, Tullia Maria, additional, Burra, Patrizia, additional, Frigo, Anna Chiara, additional, Ramirez Morales, Rafael, additional, De Carlis, Luciano, additional, Belli, Luca, additional, Colledan, Michele, additional, Fagiuoli, Stefano, additional, Rossi, Giorgio, additional, Andorno, Enzo, additional, Baccarani, Umberto, additional, Regalia, Enrico, additional, Vivarelli, Marco, additional, Donataccio, Matteo, additional, and Cillo, Umberto, additional

Published
2014
Full Text
View/download PDF

11. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list

Author

Vitale, Alessandro, primary, Volk, Michael L., additional, De Feo, Tullia Maria, additional, Burra, Patrizia, additional, Frigo, Anna Chiara, additional, Ramirez Morales, Rafael, additional, De Carlis, Luciano, additional, Belli, Luca, additional, Colledan, Michele, additional, Fagiuoli, Stefano, additional, Rossi, Giorgio, additional, Andorno, Enzo, additional, Baccarani, Umberto, additional, Regalia, Enrico, additional, Vivarelli, Marco, additional, Donataccio, Matteo, additional, and Cillo, Umberto, additional

Published
2014
Full Text
View/download PDF

12. Use of N -acetylcysteine during liver procurement: A prospective randomized controlled study

Author

D'Amico, Francesco, primary, Vitale, Alessandro, additional, Piovan, Donatella, additional, Bertacco, Alessandra, additional, Ramirez Morales, Rafael, additional, Chiara Frigo, Anna, additional, Bassi, Domenico, additional, Bonsignore, Pasquale, additional, Gringeri, Enrico, additional, Valmasoni, Michele, additional, Garbo, Greta, additional, Lodo, Enrico, additional, D'Amico, Francesco Enrico, additional, Scopelliti, Michele, additional, Carraro, Amedeo, additional, Gambato, Martina, additional, Brolese, Alberto, additional, Zanus, Giacomo, additional, Neri, Daniele, additional, and Cillo, Umberto, additional

Published
2012
Full Text
View/download PDF

15. Use of N-acetylcysteine during liver procurement: A prospective randomized controlled study.

Author

D'Amico, Francesco, Vitale, Alessandro, Piovan, Donatella, Bertacco, Alessandra, Ramirez Morales, Rafael, Chiara Frigo, Anna, Bassi, Domenico, Bonsignore, Pasquale, Gringeri, Enrico, Valmasoni, Michele, Garbo, Greta, Lodo, Enrico, D'Amico, Francesco Enrico, Scopelliti, Michele, Carraro, Amedeo, Gambato, Martina, Brolese, Alberto, Zanus, Giacomo, Neri, Daniele, and Cillo, Umberto

Published
2013
Full Text
View/download PDF

16. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: The ITA.LI.CA database

Author

Alessandro, Vitale, Gianluca, Svegliati-Baroni, Alessio, Ortolani, Monica, Cucco, Giulio V, Dalla Riva, Edoardo G, Giannini, Fabio, Piscaglia, Gianludovico, Rapaccini, Mariella, Di Marco, Eugenio, Caturelli, Marco, Zoli, Rodolfo, Sacco, Giuseppe, Cabibbo, Fabio, Marra, Andrea, Mega, Filomena, Morisco, Antonio, Gasbarrini, Francesco Giuseppe, Foschi, Gabriele, Missale, Alberto, Masotto, Gerardo, Nardone, Giovanni, Raimondo, Francesco, Azzaroli, Gianpaolo, Vidili, Filippo, Oliveri, Filippo, Pelizzaro, Rafael, Ramirez Morales, Umberto, Cillo, Franco, Trevisani, Luca, Miele, Giulio, Marchesini, Fabio, Farinati, Alessandro, Di Bucchianico, Vitale, A., Svegliati-Baroni, G., Ortolani, A., Cucco, M., Dalla Riva, G. V., Giannini, E. G., Piscaglia, F., Rapaccini, G., Di Marco, M., Caturelli, E., Zoli, M., Sacco, R., Cabibbo, G., Marra, F., Mega, A., Morisco, F., Gasbarrini, A., Foschi, F. G., Missale, G., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Oliveri, F., Pelizzaro, F., Ramirez Morales, R., Cillo, U., Trevisani, F., Miele, L., Marchesini, G., Farinati, F., Alessandro Vitale, Gianluca Svegliati-Baroni, Alessio Ortolani, Monica Cucco, Giulio V Dalla Riva, Edoardo G Giannini, Fabio Piscaglia, Gianludovico Rapaccini, Mariella Di Marco, Eugenio Caturelli, Marco Zoli, Rodolfo Sacco, Giuseppe Cabibbo, Fabio Marra, Andrea Mega, Filomena Morisco, Antonio Gasbarrini, Francesco Giuseppe Foschi, Gabriele Missale, Alberto Masotto, Gerardo Nardone, Giovanni Raimondo, Francesco Azzaroli, Gianpaolo Vidili, Filippo Oliveri, Filippo Pelizzaro, Rafael Ramirez Morales, Umberto Cillo, Franco Trevisani, Luca Miele, Giulio Marchesini, Fabio Farinati, Vitale, Alessandro, Svegliati-Baroni, Gianluca, Ortolani, Alessio, Cucco, Monica, Dalla Riva, Giulio V, Giannini, Edoardo G, Piscaglia, Fabio, Rapaccini, Gianludovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Oliveri, Filippo, Pelizzaro, Filippo, Ramirez Morales, Rafael, Cillo, Umberto, Trevisani, Franco, Miele, Luca, Marchesini, Giulio, and Farinati, Fabio

Subjects
Male, Settore MED/12 - Gastroenterologia, Carcinoma, Hepatocellular, Liver Neoplasms, nonalcoholic steatohepatitis, Gastroenterology, hepatocellular carcinoma, digestive system diseases, Non-alcoholic Fatty Liver Disease, Risk Factors, Humans, neoplasms
Abstract

BackgroundMetabolic dysfunction-associated fatty liver disease (MAFLD) represents a new inclusive definition of the whole spectrum of liver diseases associated to metabolic disorders. The main objective of this study was to compare patients with MAFLD and non-MAFLD with hepatocellular carcinoma (HCC) included in a nationally representative cohort.MethodsWe analysed 6882 consecutive patients with HCC enrolled from 2002 to 2019 by 23 Italian Liver Cancer centres to compare epidemiological and future trends in three subgroups: pure, single aetiology MAFLD (S-MAFLD); mixed aetiology MAFLD (metabolic and others, M-MAFLD); and non-MAFLD HCC.ResultsMAFLD was diagnosed in the majority of patients with HCC (68.4%). The proportion of both total MAFLD and S-MAFLD HCC significantly increased over time (from 50.4% and 3.6% in 2002–2003, to 77.3% and 28.9% in 2018–2019, respectively, pConclusionsThe prevalence of MAFLD HCC in Italy is rapidly increasing to cover the majority of patients with HCC. Despite a less favourable cancer stage at diagnosis, patients with MAFLD HCC have a lower risk of HCC-related death, suggesting reduced cancer aggressiveness.

Published
2021

17. Sexual dimorphic evolution of metabolic programming in non-genetic non-alimentary mild metabolic syndrome model in mice depends on feed-back mechanisms integrity for pro-opiomelanocortin-derived endogenous substances.

Author

Loizzo S, Vella S, Loizzo A, Fortuna A, Di Biase A, Salvati S, Frajese GV, Agrapart V, Ramirez Morales R, Spampinato S, Campana G, Capasso A, Galietta G, Guarino I, Carta S, Carru C, Zinellu A, Ghirlanda G, Seghieri G, Renzi P, and Franconi F

Subjects
11-beta-Hydroxysteroid Dehydrogenase Type 1 genetics, 11-beta-Hydroxysteroid Dehydrogenase Type 1 metabolism, 11-beta-Hydroxysteroid Dehydrogenase Type 2 genetics, 11-beta-Hydroxysteroid Dehydrogenase Type 2 metabolism, Adrenocorticotropic Hormone blood, Animals, Animals, Newborn, Brain metabolism, Corticosterone blood, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 etiology, Diabetes Mellitus, Type 2 metabolism, Female, Gene Expression Regulation, Enzymologic, Handling, Psychological, Hypothalamo-Hypophyseal System metabolism, Lipid Metabolism physiology, Male, Metabolic Syndrome blood, Metabolic Syndrome etiology, Metabolic Syndrome physiopathology, Mice, Pain Threshold physiology, Pituitary-Adrenal System metabolism, RNA, Messenger metabolism, Random Allocation, Stress, Psychological complications, Feedback, Physiological, Hypothalamo-Hypophyseal System physiopathology, Metabolic Syndrome metabolism, Pituitary-Adrenal System physiopathology, Pro-Opiomelanocortin metabolism, Sex Characteristics, Stress, Psychological physiopathology
Abstract

Previously, we showed that our post-natal handling model induces pro-opiomelanocortin-derived (POMC) endogenous systems alterations in male mice at weaning. These alterations last up to adult age, and are at the basis of adult hormonal and metabolic conditions similar to mild metabolic syndrome/type-2 diabetes. Here, we evaluate how sex influences post-natal programming in these metabolic conditions. Subjects are adult control (non-handled) female (NHF) and male (NHM) CD-1 mice; adult post-natal handled female (HF) and male (HM) mice. Handling consists of daily maternal separation (10 min) plus sham injection, from birth to weaning (21 days). In adult handled males (90-days old) we find not only POMC-derived hormones alterations (enhanced basal plasma corticosterone (+91%) and ACTH (+109%)) but also overweight (+5.4%), fasting hyperglycemia (+40%), hypertriglyceridemia (+21%), enhanced brain mRNA expression of hydroxysteroid(11-beta)dehydrogenase type-1 (HSD11B1) (+49%), and decreased mRNA-HSD11B2 (-39%). Conversely, uric acid, creatinine, HDL(C), total cholesterol, glucose and insulin incremental area under-the-curve are not affected. In females, post-natal handling does not produce both hormonal and dysmetabolic diabetes-like changes; but handling enhances n3- and n6-poly-unsaturated, and decreases saturated fatty acids content in erythrocyte membrane composition in HF versus NHF. In conclusion, for the first time we show that female sex in mice exerts effective protection against the hypothalamus-pituitary-adrenal homeostasis disruption induced by our post-natal handling model on POMC cleavage products; endocrine disruption is in turn responsible for altered metabolic programming in male mice. The role of sex hormones is still to be elucidated., (Copyright 2010 Elsevier Inc. All rights reserved.)

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results